Press "Enter" to skip to content

FDA approves first PI3K inhibitor for breast cancer

FDA approved Piqray (alpelisib) tablets, to be used in combination with the FDA-approved endocrine therapy fulvestrant.

Original source: http://www.fda.gov/news-events/press-announcements/fda-approves-first-pi3k-inhibitor-breast-cancer

Also Read:   Hepatitis C Medicines (Mavyret, Zepatier, and Vosevi): Drug Safety Communication - Due to Rare Occurrence of Serious Liver Injury in Some patients with Advanced Liver Disease